Programs testing whether target modulation changes a human-relevant phenotype, function or pathway.
R&D service
Target validation & mechanism studies
Test candidate targets in human organoids through disease phenotypes, molecular changes and treatment response.
View imageModel foundation for target studies
Validate targets in a characterized tumor model
Histology and marker profiling guide HCC PDO model selection for candidate targets. Genetic or pharmacologic perturbation studies can then connect molecular changes, functional phenotypes and drug response to support target validation and development decisions.
Study focus
Questions we can help answer
- 01How does target modulation affect the key phenotype?
- 02How do effects vary across tissues or samples?
- 03Which findings support the next experiment or program decision?
STUDY APPROACH
Match the model and assays to your program
Match tumor, disease or normal-tissue organoids to the target cell and disease context. Consider PDO 2.0 when tissue architecture or immune factors are central to the study.
Combine perturbation efficiency and target engagement with functional, pathway and dose-related readouts selected for the target and model.
Use orthogonal perturbation, negative controls and, where feasible, rescue or mechanism-relevant positive controls.
Assess the evidence for target progression and prioritize independent-sample, orthogonal, mechanism or in vivo validation.
Study workflow
Validate target modulation through human-relevant phenotypes
Test whether target modulation produces the intended disease phenotype in human organoids. Complementary perturbations, pathway assays and controls help distinguish target-specific effects.
Target hypothesis and decision criteria
Define target cell type, expected phenotype, direction of effect and evidence needed for the next decision, with progression and optimization criteria agreed upfront.
Model and baseline assessment
Select the model by tissue source, disease phenotype and target expression, then confirm the pretreatment state with histologic, functional or molecular readouts.
Orthogonal perturbation and controls
Use pharmacologic, antibody, RNA or other suitable genetic-perturbation approaches with non-targeting, vector, vehicle and appropriate positive controls.
Phenotype–pathway–dose assessment
Integrate functional phenotype, target engagement or perturbation, downstream pathway and dose/time relationships to distinguish target effects from nonspecific injury.
Target study design
Model and delivery foundation for target studies
shRNA delivery in HCC organoids provides a starting point for genetic perturbation studies. Molecular confirmation, functional phenotyping and drug-response assays can then evaluate candidate-target function.
Explore functional-genomics capabilities ↗
View imageScramble shRNA control
View imagelncRNA shRNA conditionDay-3 bright-field and green-fluorescence images show delivery signal and organoid morphology, providing a starting point for molecular and functional studies.
TRiCBIO HCC organoid lentiviral-delivery study
View imageA target-focused study connects genetic or pharmacologic perturbation with target confirmation, pathway change, functional phenotype and treatment response.
Study designExpected study outputs
What you receive
Target and model strategy
The rationale for model selection, target baseline and perturbation approach, with delivery or assay-development priorities.
Orthogonal perturbation and functional data
Perturbation efficiency, functional phenotypes, pathway readouts and control results from the prespecified assay plan.
Recommendations for the next study
Recommendations to advance the program, refine the design or focus the next experiment, linked to predefined decision criteria.
Relevant model systems
Relevant model systems
TRiCBIO brings human organoids, disease phenotypes, multimodal assays and custom genetic perturbation into target-focused studies. Each program defines delivery and perturbation performance, model selection and the statistical plan.
PROJECT DISCUSSION
Plan a target and mechanism study
Tell us the target, planned intervention, phenotype or pathway of interest, and available models or samples. Our scientists will shape the functional and mechanism study around them.